Module 3 - Strategic case studies in practice

Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities)

11.

Glossary

Chemical Transformation Step: For Chemical Entities, a step involved in the synthesis of the chemical structure of the drug substance from precursor molecular fragments. Typically it involves C-X or C-C bond formation or breaking. Contaminants: Any adventitiously introduced materials (e.g., chemical, biochemical, or microbial species) not intended to be part of the manufacturing process of the drug substance or drug product. (ICH Q6B) Continuous Process Verification: An alternative approach to process validation in which manufacturing process performance is continuously monitored and evaluated. (ICH Q8) Control Strategy: A planned set of controls, derived from current product and process understanding, that assures process performance and product quality. The controls can include parameters and attributes related to drug substance and drug product materials and components, facility and equipment operating conditions, in-process controls, finished product specifications, and the associated methods and frequency of monitoring and control. (ICH Q10) Critical Quality Attribute (CQA): A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality. (ICH Q8) Design Space: The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality. Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory post approval change process. Design space is proposed by the applicant and is subject to regulatory assessment and approval. (ICH Q8)

Intermediate: See ICH Q7, ICH Q3A, and ICH Q5C. Impurity: See ICH Q3A, ICH Q6A and ICH Q6B.

Lifecycle: All phases in the life of a product from the initial development through marketing until the product’s discontinuation. (ICH Q8) Platform Manufacturing: The approach of developing a production strategy for a new drug starting from manufacturing processes similar to those used by the same applicant to manufacture other drugs of the same type (e.g., as in the production of monoclonal antibodies using predefined host cell, cell culture, and purification processes, for which there already exists considerable experience).

25